Business Wire

Bioptimus Appoints Mathilda Strom as Founding Chief Operating Officer

14.11.2024 11:30:00 EET | Business Wire | Press release

Share

Bioptimus, a leading AI company building the Foundation Model for biology, is thrilled to announce the appointment of Mathilda Strom as its Founding Chief Operating Officer. Mathilda joins Bioptimus with an extensive track record in building pioneering businesses and a reputation as a leader in scaling impactful organizations globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114805370/en/

Mathilda Strom joins Bioptimus as Founding Chief Operating Officer (Photo: Business Wire)

With nearly 20 years of experience, Mathilda brings an entrepreneurial spirit and strategic vision to Bioptimus. Most recently, she served as the Chief Commercial Officer at CarbonPool, the world’s first insurance company to settle claims in carbon credits rather than cash.

Mathilda is no stranger to launching transformative companies. She co-founded BIMA, a microinsurance and digital health player in emerging markets. Under her leadership, BIMA expanded to 23 countries, enabling millions of low- and middle-income families to access critical financial and health services via mobile technology. Throughout her tenure, she forged deep-rooted partnerships with major global players, including Telefonica, Orange, Vodafone, Allianz, and Prudential, further cementing her reputation as an influential leader in the industry.

Beyond her executive experience, Mathilda has served on the boards of organizations like the Microinsurance Network and Azuri Technologies, a renewable energy firm working to bring solar solutions to Africa. She has earned recognition as one of the top 50 female entrepreneurs to watch and among the top 10 future women leaders in Sweden.

As Bioptimus’s new Chief Operating Officer, Mathilda Strom will oversee strategic operations, enhance organizational growth, and drive the company’s mission to fuel breakthroughs in biomedicine and beyond. Her proven expertise in building high-impact, purpose-driven ventures positions her to lead Bioptimus through its next phase of innovation and expansion.

David Cahané, Co-Founder of Bioptimus, said: ""We are thrilled to welcome Mathilda to Bioptimus as our Founding Chief Operating Officer. Her visionary leadership and track record in scaling impactful businesses align perfectly with our mission to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond. Mathilda’s expertise and commitment to innovation will be invaluable as we build the Foundation Model for biology to unlock the potential of generative AI in the field. We are excited to have her on board to help shape the future of our company.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114805370/en/

Contacts

press@bioptimus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 18:51:00 EEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye